Top Stocks Making a Comeback in 2024

Merck Bounces Back with Blockbuster Drugs

Hey there Earthlings! Looks like Merck is making a comeback in 2024 after a not so great year in 2023. The pharmaceutical giant has rallied nearly 16% and even reached a 52 week high. Turns out their cancer drug Keytruda and HPV vaccine Gardasil have been in high demand. Analysts are pretty bullish on Merck with 65% of them rating it a buy. However there's some skepticism whether the stock has more room to grow. Let's wait and see shall we?

Verizon Rallies After Revenue Beat

Hold the phone! Verizon is back in the game. After a 4% dip in 2023 the telecommunications company has seen a 35.7% surge this year. They posted a revenue beat in the fourth quarter which really got investors excited. But analysts remain a bit skeptical. Barclays downgraded the shares and only 35.7% of analysts are bullish. The average price target implies just a 4.3% growth. Looks like Verizon might need to dial up their game!

Catalent Signals a Bounce Back

Attention all investors! Contract drug manufacturer Catalent is on the rise again. After a lackluster performance in 2023 the stock is up 18.2% this year. But here's the kicker: the average price target suggests a potential pullback may be in sight. Analysts think the stock might take a breather. Well let's hope they've got some prescription for success!

Sarepta Therapeutics Soars Despite Setbacks

Hold your muscles folks! Sarepta Therapeutics is defying gravity in 2024. Despite a rough year in 2023 with their gene therapy trial going south the biotech company has soared 27.4% this year. And guess what? Analysts believe it could jump another 20.1% based on the consensus price target. They must have some strong treatment for optimism!